-

Ardent Health to Participate in May Investor Conferences

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that members of the Company's management team will participate in the following upcoming investor conferences:

  • Bank of America Securities 2025 Health Care Conference on May 13 and 14, 2025, in Las Vegas, Nevada. Members of the management team will participate in a presentation at 11:40 a.m. ET on Wednesday, May 14, 2025.
  • 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, in New York City, New York. Members of the management team will participate in a fireside chat at 8:00 a.m. ET that same day.

A live audio webcast of these presentations will be available in the Investor Relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.

In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations at investor.relations@ardenthealth.com.

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Contacts

Investor Contact:
Dave Styblo, CFA

SVP, Investor Relations
investor.relations@ardenthealth.com
(615) 296-3016

Media Contact:
Rebecca Kirkham
SVP, Communications & Corporate Affairs
rebecca.kirkham@ardenthealth.com
(615) 296-3635

Ardent Health

NYSE:ARDT

Release Versions

Contacts

Investor Contact:
Dave Styblo, CFA

SVP, Investor Relations
investor.relations@ardenthealth.com
(615) 296-3016

Media Contact:
Rebecca Kirkham
SVP, Communications & Corporate Affairs
rebecca.kirkham@ardenthealth.com
(615) 296-3635

More News From Ardent Health

Ardent Health Marks Expansion of Specialty Care in New UT Tyler School of Medicine

BRENTWOOD, Tenn. & TYLER, Texas--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today marked a milestone in its East Texas partnership as UT Health East Texas expanded specialty care into the new UT Tyler School of Medicine Building in Tyler – the first time patient services and physician training share a single hub in the region. The building now houses UT Health East Texas women's health, pulmonary, orthope...

Ardent Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, in Boston, Massachusetts. Members of the management team will participate in a fireside chat on September 9, 2026, at 11 a.m. ET. A live audio webcast of the event will be available in the Investor Relations sec...

Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region

BRENTWOOD, Tenn. & TULSA, Okla.--(BUSINESS WIRE)--Oklahoma Heart Institute (OHI), part of Hillcrest HealthCare System and Ardent Health (NYSE: ARDT), is now the only site in Oklahoma and the surrounding region participating in several leading national cardiovascular trials – and recently became the first in the United States to use the next-generation Supira percutaneous left ventricular assist device (pVAD) as part of the SUPPORT II clinical trial. Through this research, OHI is expanding acces...
Back to Newsroom